RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 65 filers reported holding RA PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $78,988,000 | +2.8% | 1,645,236 | +0.5% | 0.01% | +40.0% |
| Q4 2019 | $76,822,000 | +97.4% | 1,636,941 | -0.5% | 0.01% | +66.7% |
| Q3 2019 | $38,913,000 | -13.9% | 1,645,369 | +9.5% | 0.00% | 0.0% |
| Q2 2019 | $45,200,000 | +115.8% | 1,503,151 | +60.8% | 0.00% | +50.0% |
| Q1 2019 | $20,946,000 | +391.6% | 935,076 | +299.4% | 0.00% | – |
| Q4 2018 | $4,261,000 | +14.4% | 234,101 | +13.7% | 0.00% | – |
| Q3 2018 | $3,725,000 | +99.8% | 205,832 | +10.0% | 0.00% | – |
| Q2 2018 | $1,864,000 | +87.0% | 187,115 | -0.1% | 0.00% | – |
| Q1 2018 | $997,000 | -26.1% | 187,249 | +17.9% | 0.00% | – |
| Q4 2017 | $1,349,000 | -40.5% | 158,773 | +2.1% | 0.00% | – |
| Q3 2017 | $2,269,000 | -19.8% | 155,522 | +3.0% | 0.00% | – |
| Q2 2017 | $2,830,000 | +23.4% | 151,063 | +40.3% | 0.00% | – |
| Q1 2017 | $2,294,000 | +116.4% | 107,687 | +54.5% | 0.00% | – |
| Q4 2016 | $1,060,000 | – | 69,688 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |